Scott Alan Peslak, MD, PhD

he/him/his
Hematology
Accepting new patients
Sees patients age 18 and up
Penn Blood Disorders Center
Make an appointmentCall 215-615-6555
Headshot of Scott Alan Peslak, MD, PhD
Penn Medicine Provider

About me

  • Gene Therapy Lead, Comprehensive Sickle Cell Program and Comprehensive Adult Thalassemia Program
  • Assistant Professor of Medicine (Hematology-Oncology)
  • Assistant Professor of Pediatrics

I am a physician-scientist at the University of Pennsylvania and I care for patients in the Penn Medicine Comprehensive Sickle Cell Disease Program and Comprehensive Adult Thalassemia Program. In addition to my clinical focus on red cell disorders, I also run a laboratory studying novel regulators of fetal hemoglobin and new genetic and pharmacologic therapies for the treatment of sickle cell disease.

My education and training

  • Medical School: University of Rochester School of Medicine
  • Residency: University of Pennsylvania Health System
  • Fellowship: University of Pennsylvania Health System

Spoken languages

English
English

Reviews

Average Rating

84 reviews

Comments are submitted by patients and reflect their views and opinions. The comments are not endorsed by and do not necessarily reflect the views of Penn Medicine.

Anonymous
May 2026
great clinician
Anonymous
April 2026
comfort , relax
Anonymous
April 2026
he was empathetic, understanding and addressed my needs without judgement
Anonymous
February 2026
listen and knowledge and expertise

Insurance accepted

Please contact the practice and/or the member services department of your insurance company for specific details before receiving services. Providers may participate in some, but not all, products offered by a health plan; providers may also accept plans at some practice locations but not others.

Locations

Penn Medicine hospital privileges

  • Hospital of the University of Pennsylvania: Has privileges to treat patients in the hospital.
Dr. Peslak is a Penn Medicine physician.

Qualifications and experience

Treatments and Conditions

Research

Publications

Cheng A.N., Peslak S.A., Sheth S., Sayani F., Lal A. High morbidity in adults with non-transfusion-dependent thalassemia referred to U.S. specialty centers , American Society of Hematology Annual Meeting, Orlando, FL: 2025

Castracani C.C., Bright M., Patel J., Peslak S.A., Cheng A., Breda L., Rivella S., Kwiatkowski J. Real-world comparative effects of curative and disease-modifying therapies on ineffective erythropoiesis in beta-thalassemia , American Society of Hematology Annual Meeting, Orlando, FL: 2025

Cheng A.N., Gimotty P., Margolis D., Peslak S.A., Al-Samkari H, Roe A.H., Kwiatkowski J.L. Development of a Prediction Model for Maternal Pregnancy Complications in Sickle Cell Disease , American Society of Hematology Annual Meeting, Orlando, FL: 2025

Sheth S., Lal A., Appiah-Kubi A, Peslak S.A., Temin N.T., Coates T. Real-world safety profile of twice-daily deferiprone for iron overload in patients with thalassemia syndromes , 20th Annual Sickle Cell and Thalassemia Conference (ASCAT), London, UK: 2025

Sheth S., Lal A., Appiah-Kubi A, Peslak S.A., Temin N.T., Coates T. Real-world safety profile of twice-daily deferiprone for iron overload in patients with sickle cell disease , 20th Annual Sickle Cell and Thalassemia Conference (ASCAT), London, UK: 2025

Cheng A.N, Peslak S.A., Sheth S., Sayani S., Lal A. High Morbidity in Adults with Non-Transfusion-Dependent Thalassemia Referred to U.S. Specialty Centers , 20th Annual Sickle Cell and Thalassemia Conference (ASCAT), London, UK: 2025

Al Ta’ani, O.; Mayrer, B.M.; Luche, N.M.; Siddique, S.M., Peslak, S.A.; Anderson, T.S.; Vajravelu, R.K. Impact of Diagnostic Serum Ferritin Thresholds on Prevalence of Iron Deficiency Anemia: A Cross-Sectional Analysis of U.S. Adults , JAMA Internal Medicine, Online Ahead of Print: 2025,e252311

Cheng A.N., Cohen J., Lundberg R.K., Sayani F.A., Chong E.A., Peslak S.A. Progressive Anaemia and Splenomegaly in an Adult with HbE/Beta Thalassaemia , 1st TIF Pan American Conference on Thalassaemia and Other Haemoglobin Disorders, Washington, DC.: 2025

Huang, P., Peslak, S.A., Shehu, V., Keller, C.A., Giardine, B., Shi, J., Hardison, R.C., Blobel, G.A., Khandros, E. Let-7 miRNAs repress HIC2 to regulate BCL11A transcription and hemoglobin switching , Blood, 143(19): 2024,1980-1991

Peslak S.A., Abbas T., Khandros E., Traxler E.A., Abdulmalik O., Giardine B.M., Keller C.A., Hardison R.C., Shi J., Blobel G.A. Protein Phosphatase 6 Complex: Novel Regulator of Fetal Hemoglobin and Potential Therapeutic Target in Sickle Cell Disease. , American Society of Hematology Annual Meeting, San Diego, CA: 2023

View all publications